Your search for colorectal cancer returned 683 results

Survival advantage greatest for diagnosis at age 35 through 39 years with stage I or II disease versus diagnosis at age 51 to 55 years

Multitarget stool DNA test, fecal immunochemical test, or guaiac-based fecal occult blood test preferred over colonoscopy

Recommendation strong for screening average-risk individuals from age 50 to 75 years; recommendation conditional for screening from age 45 years

Review of meta-analyses of prospective observational studies reveals lower risk with higher intakes of dietary fiber, dietary calcium, yogurt

The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Patients with colorectal cancer and diabetes have better survival with adherence to diabetes meds.

The FDA has approved Braftovi® (encorafenib; Pfizer) in combination with cetuximab (Erbitux®; Lilly) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Taking statins before or after cancer diagnosis cuts all-cause and cancer-related deaths

Significant association for men, with positive but not statistically significant link seen for women

The approval was based on data from the ongoing Phase 2 CheckMate-142 study which enrolled patients with MSI-H/dMMR metastatic CRC who had received ≥1 prior line of therapy for metastatic disease (N=119).